These findings underscore that, in addition to hormone receptor (HR) status, HER2 status, and programmed death ligand 1 (PD-L1) status in triple-negative breast cancer (TNBC), information about BRCA1/2mut status is also an essential factor in determining choice of therapy. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.